Pre-market hot trades in US stocks: Quhuo fell 6.10% in pre-market trading, with clear capital flow but no significant news. What is causing the market sentiment to fluctuate?

Pre-market Hot Trades in US Stocks Quhuo fell 6.10% in pre-market trading. There has been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news Top Gainers in Pre-market US Stocks 707 rose 48.27% in pre-market trading, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Veea rose 36.63% in pre-market trading. Based on recent news, On February 27, Veea announced that it would showcase its new TerraFabric control plane at the 2026 Mobile World Congress in Barcelona. This technology aims to help organizations streamline the management of AI workloads, providing automated management, policy execution, and software lifecycle management capabilities. This news boosted market confidence in Veea's technological prospects, driving the stock price up. On February 26, Veea issued a press release reminding investors that its future performance may differ significantly from expectations and emphasized various uncertainties and risks. Nevertheless, market expectations for its technological innovations remain high, further driving the stock price up. On February 23, Veea released relevant content through the EDGAR system of the U.S. Securities and Exchange Commission, further enhancing market confidence in its information transparency, promoting the rise in stock price. Recently, the technology sector has performed strongly overall, with increased investor interest in innovative technologies. Neurogene rose 30.44% in pre-market trading. Based on recent key news: On February 26, Neurogene announced that its gene therapy NGN-401 for Rett syndrome received breakthrough therapy designation from the U.S. FDA. This designation is based on interim efficacy and safety data from Phase 1/2 trials as of October 30, 2025, significantly boosting the stock price. Source: Reuters On February 26, Neurogene expects to complete dosing in its Embolden registration trial by the second quarter of 2026. This news enhanced market confidence in its R&D progress, further driving the stock price up. Source: Reuters On February 26, Neurogene's NGN-401 received multiple U.S. and international designations, demonstrating its strong potential in the rare neurogenetic disease market, boosting investor confidence. Source: Public Technologies The biotechnology industry has recently received policy support, with significant capital inflows